Bryan Garnier - Media Analytics Corp (MEDA) MEDARTIS: 1H19 beat highlights resilience in Extremities | BUY | CHF57(+49%)

Report

Bryan Garnier

Dylan Van Haaften

MEDARTIS: 1H19 beat highlights resilience in Extremities | BUY | CHF57(+49%)

MEDARTIS - BUY | CHF57(+49%)
1H19 beat highlights resilience in Extremities

1H19 beats +12% on revenue vs consensus
Trauma surgery demand remains robust in spite of COVID
Managing cost and FX likely to remain volatile in 2H19
Re-iterate Buy and FV CHF57

18/08/2020 3 EN

Underlying

Media Analytics Corp

See profile

US5843932014 Pink OTC Markets United States

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Dylan Van Haaften

Other Reports on these Companies

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Bryan Garnier

MEDARTIS: Remove Medartis from top picks after strong performance | BUY | CHF80(-11%)

MEDARTIS - BUY | CHF80(-11%) Remove Medartis from top picks after strong performance Medartis doubled YTD, and returned 28% since entering top picks Extremities still offers great growth to LT investors Largest opportunities still ahead Retain BUY TP CHF80, inorganic growth key catalyst for share

June 10, 2021 June 10, 2021 4 EN

Bryan Garnier

MEDARTIS: Reaching for the stars, in post-COVID extremities | BUY | CHF80 VS. 60(-2%)

MEDARTIS - BUY | CHF80 VS. 60(-2%) Reaching for the stars, in post-COVID extremities US strategy paying off KeriMedical allows Medartis to touch new markets More M&A on the agenda Update estimates TP EUR 80 (from EUR 60), retain BUY

March 30, 2021 March 30, 2021 3 EN

Median Technologies: reports Q1 2024 results

Median reconfirmed previously shared FY 2023 and reported Q1 2024 results this morning. FY 2023 sales were confirmed at EUR 22.2m representing a 7% drop vs. 2022, as iCRO business has been hampered by the COVID crisis in China. While the first three-quarter 2023 revenues were stable at ~5.6m per qu

13h / 6m 13h / 6m 1 EN

Clement Genelot

Clement Genelot

Jeronimo Martins: Q1 topping expectations; price war ongoing in Poland

With Q1 topping expectations in terms of both sales and EBITDA, notably thanks to Biedronla, we foresee a positive share price reaction this morning. But reiterated gloomy FY guidance combined with no early signs of the price war easing in Poland still suggests caution is advisable.

14h / 42m 14h / 42m 1 EN

Paul de Froment ... (+3)

Paul de Froment
Sebastián Marroquin Mérida
Thomas Mordelle

Nel: Capacity reservation agreement with Hy Stor Energy

This morning, Nel announced a multi-year capacity reservation agreement (CRA) with Hy Stor Energy, representing more than 1GW of alkaline electrolyser capacity combined over 2025/2027, for its Mississippi Clean Hydrogen Hub (MCHH) project. The project is still pending regulatory approvals, financin

14h / 54m 14h / 54m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

MEDARTIS: 1H19 beat highlights resilience in Extremities | BUY | CHF57(+49%)

Monthly LMI Update Independent Investment Research

MEDARTIS: Remove Medartis from top picks after strong performance | BUY | CHF80(-11%)

MEDARTIS: Reaching for the stars, in post-COVID extremities | BUY | CHF80 VS. 60(-2%)

Median Technologies: reports Q1 2024 results

Jeronimo Martins: Q1 topping expectations; price war ongoing in Poland

Nel: Capacity reservation agreement with Hy Stor Energy

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe